| abstract |
The invention discloses an intestinal flora marker for predicting the curative effect of immunotherapy and application thereof. The inventor screens DNA detection targets with expression difference in patients with different clinical curative effects from 55 intestinal bacteria DNA detection targets, and can solve the problems of few available biomarkers and unsatisfactory effect in melanoma immunotherapy patients. The relationship of gut flora characteristics to PD-1/PD-L1 blockade therapy may have commonalities in different classes of tumors; the research result of the project is subjected to data supplement and reanalysis, and has the possibility of being applied to tumors except melanoma, such as sarcoma, renal cancer, lung cancer, gastric cancer or colorectal cancer, and enabling patients to benefit. |